Pharmacokinetic differences between lansoprazole enantiomers in rats

Journal of Pharmacy and Pharmacology

Volumn 50, Issue 11, 1998, Pages 1241-1245

  Arimori, Kazuhiko ^a   Yasuda, Kazuto ^a   Katsuki, Hisakazu ^a   Nakano, Masahiro ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LANSOPRAZOLE; STOMACH SECRETION INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; ENANTIOMER; LIVER METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0031762546     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1998.tb03340.x     Document Type: Article

References (16)

1. Andersson, T., Regardh, C. G., Dahl-Puustinen, M. L., Bertilsson, L. (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther. Drug Monit. 12: 415-416
2. Arimori, K., Nakano, M. (1987) The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats. J. Pharmacobiodyn. 10: 157-165
3. Jeffrey, P., Tucker, G. T., Bye, A., Crewe, H. K., Wright, P. A. (1991) The site of inversion of R-(-)-ibuprofen: studies using rat in-situ isolated perfused intestine/liver preparations. J. Pharm. Pharmacol. 43: 715-720
4. Katsuki, H., Yagi, H., Arimori, K., Nakamura, C., Nakano, M., Katafuchi, S., Fujioka, Y., Fujiyama, S. (1996) Determination of R-(+)- and S-(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm. Res. 13: 611-615
5. Katsuki, H., Nakamura, C., Arimori, K., Fujiyama, S., Nakano, M. (1997) Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur. J. Clin. Pharmacol. 52: 391-396
6. Lowry, O. H., Rosebrough, A. L., Farr, A. L., Randall, R. L. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275
7. Miwa, K., Mitani, M., Tsukamoto, T., Yoshida, K., Kobayashi, T., Kimura, T., Simomura, H., Tanayama, S. (1990) Metabolic fate of AG-1749, a new proton pump inhibitor, in rats, mice, and dogs. Jpn Pharmacol. Ther. 18: 3413-3435
8. +)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells. Biochem. Pharmacol. 42: 1875-1878
9. Pichard, L., Curi-Pedrosa, R., Bonfils, C., Jacqz-Aigrain, E., Domerque, J., Joyeux, H., Cosme, J., Guengerich, F. P., Maurel, P. (1995) Oxidative metabolism of lansoprazole by human liver microsomes. Mol. Pharmacol. 47: 410-418
10. Sohn, D. R., Kwon, J. T., Kim, H. K., Ishizaki, T. (1997) Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin. Pharmacol. Ther. 61: 574-582
11. Tateno, M., Nakamura, N. (1991) Phase I study of lansoprazole (AG-1749) antiulcer agent-Capsule form. Rinsho Iyaku 7: 51-62
12. Tomimaru, A., Arimori, K., Inotsume, N., Nakano, M. (1996) Effect of activated charcoal and atropine on absorption and/or exsorption of organophosphorus compounds in rats. J. Pharm. Pharmacol. 48: 351-356
13. Tsuruta, S., Nakamura, K., Arimori, K., Nakano, M. (1997) Effects of erythromycin, clarithromycin and rokitamycin on nifedipine metabolism in rats. Biol. Pharm. Bull. 20: 411-416
14. Tybring, G., Bottiger, Y., Widen, J., Bertilsson, L. (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin. Pharmacol. Ther. 62: 129-137
15. Uematsu, T., Nakano, M., Kosuge, K., Nagai, A., Sato, A., Nakashima, M. (1994) Pharmacokinetic properties of a novel gastric proton-pump inhibitor, (±)-2-(4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl) sulfinyl-1H-benzimidazole sodium salt, in healthy subjects. J. Pharm. Sci. 83: 1407-1411
16. Wallmark, B., Jaresten, B. M., Larsson, H., Ryberg, B., Brandstrom, A., Fellenius, E. (1983) Differentiation among inhibitory actions of omeprazole, cimetidine and SCN on gastric acid secretion. Am. J. Physiol. 245: G64-G71